Fulton Bank N.A. Has $2.42 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Fulton Bank N.A. increased its stake in Pfizer Inc. by 24.8%, acquiring an additional 19,852 shares to reach a total of 99,760 shares valued at $2.4 million.
• Pfizer's latest quarterly earnings revealed $0.78 EPS, which exceeded analysts' expectations of $0.58, contributing to a 10.3% year-over-year revenue growth to $14.65 billion.
• The company's recent dividend of $0.43 per share represents a 7.2% yield, with a payout ratio of approximately 91.49%.

Fulton Bank N.A. grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 24.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,760 shares of the biopharmaceutical company's stock after acquiring an additional 19,852 shares during the period. Fulton Bank N.A.'s holdings in Pfizer were worth $2,418,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares during the period. Vident Advisory LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $248,000. Woodline Partners LP boosted its holdings in shares of Pfizer by 17.0% during the 4th quarter. Woodline Partners LP now owns 1,318,490 shares of the biopharmaceutical company's stock worth $34,980,000 after buying an additional 191,957 shares during the period. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Pfizer by 27.3% during the 4th quarter. Voloridge Investment Management LLC now owns 2,402,685 shares of the biopharmaceutical company's stock worth $63,743,000 after buying an additional 515,836 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.11 during midday trading on Thursday, hitting $24.16. The stock had a trading volume of 34,232,417 shares, compared to its average volume of 40,033,748. The company's 50-day moving average price is $24.67 and its 200-day moving average price is $24.23. The company has a market capitalization of $137.33 billion, a P/E ratio of 12.85, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer's payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.